Floatz logo

Adv-Tk

Malignant Pleural Effusion

Candel Therapeutics, Inc.gene_therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Malignant Pleural Effusion cohort.

Asset / SponsorPhaseRating
Carboplatin
University of Washington
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Chinese PLA General Hospital
Phase 3BB
Docetaxel
University of Washington
Phase 2B
Bortezomib
National Cancer Institute (NCI)
Phase 2B
Cetuximab
National Cancer Institute (NCI)
Phase 2B

View all 19 →

Same molecule, other indications

Adv-Tk is also rated in:

brain gliomaDormant
B
Indicative ·
57 / 100
View asset →
disease related to solid organ transplantationDormant
B
Indicative ·
57 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →